Form 4: Madrigal Pharmaceuticals Director Receives Stock Grant

Rebecca Taub, a Director at Madrigal Pharmaceuticals, was granted restricted stock units and stock options on June 17, 2026.

Summary

• Rebecca Taub, a Director at Madrigal Pharmaceuticals, Inc. (MDGL), received a grant of restricted stock units (RSUs) and stock options on June 17, 2026.
• The RSUs, totaling 454 units, vest on the earlier of June 17, 2027, or the Issuer's annual meeting of stockholders in 2027, provided she remains in service.
• Additionally, Taub was granted stock options to purchase 766 shares of common stock at an exercise price of $499.86 per share.
• These stock options also vest on the earlier of June 17, 2027, or the Issuer's annual meeting of stockholders in 2027, contingent on continued service.
• Following these transactions, Taub directly owns 452,667 shares of common stock and indirectly owns 655,540 shares through SQN LLC, of which she is a managing member.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting standard compensation practices for a director rather than significant company performance news.

Positives

• Director Rebecca Taub received a grant of restricted stock units and stock options, indicating continued investment in her role and the company's future.
• The vesting schedule for both RSUs and stock options is tied to continued service, aligning the director's incentives with the company's long-term success.
• Taub's indirect beneficial ownership through SQN LLC suggests a broader commitment to the company's equity.

Negatives

• The filing does not contain any negative financial results or operational setbacks.

Risks

• Vesting of RSUs and stock options is contingent on continued service, meaning any departure from the company before the vesting date would result in forfeiture.
• The value of the granted securities is subject to market fluctuations and the future performance of Madrigal Pharmaceuticals' stock.

Future Outlook

The future outlook is tied to the vesting of the granted RSUs and stock options, which are contingent on continued service and specific future dates, implying a focus on long-term employee retention and performance.

Management Comments

• The filing includes a disclaimer from Rebecca Taub regarding beneficial ownership of securities held by SQN LLC, stating she disclaims beneficial ownership except to the extent of her pecuniary interest and that the inclusion does not constitute an admission of beneficial ownership for Section 16 purposes.
• The signature is provided by Mardi Dier as Attorney-in-Fact for Rebecca Taub.

Industry Context

StockSavvy.ai notes that grants of equity awards like RSUs and stock options are standard practice in the pharmaceutical industry to attract, retain, and incentivize key personnel, particularly at the director level, aligning their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The grant of equity to a director aligns their interests with shareholders, potentially leading to decisions that enhance long-term shareholder value. The indirect ownership through SQN LLC also indicates a continued stake.
• Employees: The vesting conditions for Taub's awards highlight the importance of continued service, a common incentive structure that can indirectly influence employee retention and performance expectations.
• Management: The transaction reflects standard executive compensation practices within the industry.

Next Steps

• Vesting of restricted stock units on the earlier of June 17, 2027, or the Issuer's annual meeting of stockholders in 2027.
• Vesting of stock options on the earlier of June 17, 2027, or the Issuer's annual meeting of stockholders in 2027.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, Form 4, SEC Filing, Stock Options, Restricted Stock Units, Insider Trading, Director Compensation, Beneficial Ownership, Equity Grant